Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cytarabine 85Cyclophosphamide 58Azacitidine 57fludarabine 52venetoclax 41fludarabine phosphate 41Busulfan 30Filgrastim 23Whole-Body Irradiation 22Decitabine 21Mycophenolic Acid 20Methotrexate 19Mitoxantrone 18Etoposide 18Antilymphocyte Serum 18Cyclosporine 17Clofarabine 17Tacrolimus 16Granulocyte Colony-Stimulating Factor 16Peripheral Blood Stem Cell Transplantation 15Daunorubicin 15Melphalan 13thymoglobulin 11Thiotepa 11Stem Cell Transplantation 11Interleukin-2 11Idarubicin 10Gemtuzumab 9Cord Blood Stem Cell Transplantation 9aldesleukin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myeloid, Acute × TAK-659 × Clear all
NCT04079738 2023-09-13

Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib

Big Ten Cancer Research Consortium

Phase 1/2 Terminated
8 enrolled 10 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02323113 2023-02-08

Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)

Calithera Biosciences, Inc

Phase 1/2 Terminated
43 enrolled 27 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡